KYUNG DONG PHARMACEUTICAL Co., Ltd 011040

KRX · South Korea · Health Technology

KRW 5,020.00+10.00 (+0.20%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

KYUNG DONG PHARMACEUTICAL Co., Ltd 011040

KRX · South Korea · Health Technology

KRW 5,020.00+10.00 (+0.20%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-7.04% · 6MFull-screen chart

Open KRW 5,010.00High KRW 5,050.00Low KRW 5,000.00Close KRW 5,020.00Volume 7.74K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 5,010.00
Day range: KRW 5,000.00 – KRW 5,050.00
52-week range: KRW 4,700.00 – KRW 6,270.00
Volume: 7.74K
Market cap: KRW 135.07B
P/E (TTM): 7.7
Dividend yield (annualized): 5.99%
Avg. volume (1Y): 46.42K

Performance

1 week

0.00%

1 month

-0.79%

3 months

-0.59%

6 months

-6.52%

Year to date

-12.54%

1 year

-11.43%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Generic
Country: South Korea
Exchange: KRX
Shares outstanding: 29.30M
Employees: 363
ISIN: KR7011040003
Beta: 0.20

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 09, 2026

Kyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar Antibody

BOSTON, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kyungdong Pharmaceutical announced that it has successfully completed a cell line development campaign for a biosimilar antibody candidate, in collaboration with Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development. Through this collaboration, Kyungdong secured a high-performing production cell line for its next-generation biosimilar antibody candidate, laying the foundation for process development, larg

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.